List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1047186/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Psychological Characteristics of Patients with Takotsubo Syndrome and Patients with Acute Coronary Syndrome: An Explorative Study toward a Better Personalized Care. Journal of Personalized Medicine, 2022, 12, 38.	2.5	4
2	Twelve Variants Polygenic Score for Lowâ€Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	3.7	12
3	Persistent long-term platelet activation and endothelial perturbation in women with Takotsubo syndrome. Biomedicine and Pharmacotherapy, 2021, 136, 111259.	5.6	7
4	Effects of Mediterranean Diet or Low-Fat Diet on Blood Fatty Acids in Patients with Coronary Heart Disease. A Randomized Intervention Study. Nutrients, 2021, 13, 2389.	4.1	5
5	Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines, 2020, 8, 535.	4.4	102
6	Impact of BDNF Val66Met Polymorphism on Myocardial Infarction: Exploring the Macrophage Phenotype. Cells, 2020, 9, 1084.	4.1	19
7	Overall dietary variety and adherence to the Mediterranean diet show additive protective effects against coronary heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1315-1321.	2.6	12
8	Gene-expression profiles of abdominal perivascular adipose tissue distinguish aortic occlusive from stenotic atherosclerotic lesions and denote different pathogenetic pathways. Scientific Reports, 2020, 10, 6245.	3.3	8
9	Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials. Current Pharmaceutical Design, 2020, 26, 11-24.	1.9	7
10	Trials in "True―Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 960-967.	4.7	2
11	Genome-Wide Expression Profiling Unveils Autoimmune Response Signatures in the Perivascular Adipose Tissue of Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 237-249.	2.4	35
12	Update of green tea interactions with cardiovascular drugsÂandÂputative mechanisms. Journal of Food and Drug Analysis, 2018, 26, S72-S77.	1.9	39
13	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.8	48
14	Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis. Global Heart, 2018, 13, 27.	2.3	13
15	BDNFVal66met polymorphism: a potential bridge between depression and thrombosis. European Heart Journal, 2017, 38, ehv655.	2.2	49
16	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
17	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
18	Assessing Free-Radical-Mediated DNA Damage during Cardiac Surgery: 8-Oxo-7,8-dihydro-2â€2-deoxyguanosine as a Putative Biomarker. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	4.0	6

#	Article	IF	CITATIONS
19	Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. Open Heart, 2016, 3, e000438.	2.3	36
20	Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention. Current Pharmaceutical Design, 2015, 21, 1164-1171.	1.9	35
21	A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. International Journal of Cardiology, 2015, 183, 47-53.	1.7	48
22	Overview of Green Tea Interaction with Cardiovascular Drugs. Current Pharmaceutical Design, 2015, 21, 1213-1219.	1.9	24
23	Nitric Oxide Synthetic Pathway in Patients with Microvascular Angina and Its Relations with Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	4.0	18
24	Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2014, 95, 432-438.	4.7	114
25	Response to "The Effect of Green Tea With Exceptionally High Catechin Content on Nadolol Plasma Concentrationâ€: Clinical Pharmacology and Therapeutics, 2014, 95, 589-589.	4.7	1
26	Development of rapid and simultaneous quantitative method for green tea catechins on the bioanalytical study using UPLC/ESIâ€MS. Biomedical Chromatography, 2013, 27, 1-6.	1.7	27
27	Effects of smoking regular or light cigarettes on brachial artery flow-mediated dilation. Atherosclerosis, 2013, 228, 153-160.	0.8	29
28	Green Tea Extract Affects the Cytochrome P450 3A Activity and Pharmacokinetics of Simvastatin in Rats. Drug Metabolism and Pharmacokinetics, 2013, 28, 514-518.	2.2	31
29	Oxidative stress and nitric oxide pathway in adult patients who are candidates for cardiac surgery: patterns and differences. Interactive Cardiovascular and Thoracic Surgery, 2013, 17, 923-930.	1.1	21
30	Effects of Green Tea Catechins on Cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A Activities in Human Liver and Intestinal Microsomes. Drug Metabolism and Pharmacokinetics, 2013, 28, 244-249.	2.2	85
31	Nitric Oxide Synthetic Pathway in Red Blood Cells Is Impaired in Coronary Artery Disease. PLoS ONE, 2013, 8, e66945.	2.5	42
32	Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB Journal, 2012, 26, 1323-1333.	0.5	56
33	The metabolic syndrome predicts carotid intima-media thickness no better than the sum of individual risk factors in a lipid clinic population. Atherosclerosis, 2010, 210, 214-219.	0.8	14
34	Effects of Timing and Extent of Smoking, Type of Cigarettes, and Concomitant Risk Factors on the Association Between Smoking and Subclinical Atherosclerosis. Stroke, 2009, 40, 1991-1998.	2.0	37
35	Assessment of oxidative stress in coronary artery bypass surgery: comparison between the global index OXY-SCORE and individual biomarkers. Biomarkers, 2009, 14, 465-472.	1.9	20
36	Tissue factor gene promoter haplotype associates with carotid intima-media thickness in subjects in cardiovascular risk prevention. Atherosclerosis, 2009, 207, 168-173.	0.8	10

#	Article	IF	CITATIONS
37	Carotid intimaâ€media thickness and markers of inflammation, endothelial damage and hemostasis. Annals of Medicine, 2008, 40, 21-44.	3.8	78
38	Patients with a history of stable or unstable coronary heart disease have different acute phase responses to an inflammatory stimulus. Atherosclerosis, 2008, 196, 835-840.	0.8	13
39	The Effect of Green Tea on Simvastatin Tolerability. Annals of Internal Medicine, 2008, 149, 286.	3.9	31
40	A new compound-specific pleiotropic effect of statins: Modification of plasma gamma-tocopherol levels. Atherosclerosis, 2007, 193, 229-233.	0.8	15
41	Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent. International Journal of Molecular Medicine, 2006, 17, 539.	4.0	2
42	Association between Erectile Dysfunction and Coronary Artery Disease: Matching the Right Target with the Right Test in the Right Patient. European Urology, 2006, 50, 721-731.	1.9	203
43	Sialic acid as a protective barrier against neointima development. Atherosclerosis, 2005, 181, 225-231.	0.8	17
44	Statins in Atherothrombosis. Seminars in Vascular Medicine, 2004, 4, 407-415.	2.1	6
45	Hyperhomocysteinemia Induces Renal Hemodynamic Dysfunction: Is Nitric Oxide Involved?. Journal of the American Society of Nephrology: JASN, 2003, 14, 653-660.	6.1	37
46	Arteriogenesis Induced by Intramyocardial Vascular Endothelial Growth Factor 165 Gene Transfer in Chronically Ischemic Pigs. Human Gene Therapy, 2003, 14, 1307-1318.	2.7	43
47	Statins in coronary bypass surgery: rationale and clinical use. Annals of Thoracic Surgery, 2003, 76, 2132-2140.	1.3	38
48	Marked neointimal lipoprotein lipase increase in distinct models of proclivity to atherosclerosis: a feature independent of endothelial layer integrity. Atherosclerosis, 2001, 156, 91-101.	0.8	14
49	Injury produces early rise in lipoprotein lipase activity in rabbit aorta. Atherosclerosis, 1996, 125, 257-266.	0.8	4
50	Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. Biomedical Applications, 1996, 687, 437-442.	1.7	39
51	Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia*. Clinical Pharmacology and Therapeutics, 1995, 57, 434-440.	4.7	14
52	Drug control of reverse cholesterol transport. , 1994, 61, 289-324.		33
53	Common carotid intima-media thickness measurement. A method to improve accuracy and precision Stroke, 1994, 25, 1588-1592.	2.0	60
54	Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase-activities. Metabolism: Clinical and Experimental, 1993, 42, 229-235.	3.4	37

#	Article	IF	CITATIONS
55	Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis, 1993, 101, 203-211.	0.8	54
56	Dose-Related Increase of HDL-cholesterol Levels after N-acetylcysteine in Man. Pharmacological Research, 1993, 28, 213-218.	7.1	18
57	Tolerability of fibric acids. comparative data and biochemical bases. Pharmacological Research, 1992, 26, 243-260.	7.1	19
58	Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. European Journal of Clinical Pharmacology, 1992, 43, 219-223.	1.9	42
59	Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. Atherosclerosis, 1990, 84, 41-48.	0.8	28